Catalyst Wire Dossier Catalyst Wire Dossier

Anti-CD22 CAR-T cells

· National Cancer Institute (NCI)
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Anti-CD22 CAR-T cells, covering 2026-03-31 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies [Phase 1]

See pricing